Tadalafil
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Benign Prostatic Hyperplasia
Conditions
Benign Prostatic Hyperplasia
Trial Timeline
Jul 1, 2010 → Apr 1, 2011
NCT ID
NCT01183650About Tadalafil
Tadalafil is a phase 1 stage product being developed by Eli Lilly for Benign Prostatic Hyperplasia. The current trial status is completed. This product is registered under clinical trial identifier NCT01183650. Target conditions include Benign Prostatic Hyperplasia.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (13)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02252367 | Approved | Completed |
| NCT02224846 | Approved | Completed |
| NCT01326117 | Approved | Withdrawn |
| NCT01324999 | Phase 2/3 | Completed |
| NCT01183650 | Phase 1 | Completed |
| NCT01066845 | Pre-clinical | Completed |
| NCT00822354 | Pre-clinical | Completed |
| NCT00157326 | Phase 2 | Completed |
| NCT00333281 | Approved | Completed |
| NCT00422578 | Approved | Completed |
| NCT00421083 | Phase 3 | Completed |
| NCT00547417 | Phase 3 | Completed |
| NCT00547599 | Approved | Completed |
Competing Products
20 competing products in Benign Prostatic Hyperplasia